Comparison of Mortality Rates Between Patients With Diffuse Large B Cell Lymphoma Surviving 5 Years After Initial Diagnosis and a Matched General Population Cohort

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-03-20 DOI:10.1002/cam4.70800

John Acquavella, Dóra Körmendiné Farkas, Henrik Toft Sørensen

{"title":"Comparison of Mortality Rates Between Patients With Diffuse Large B Cell Lymphoma Surviving 5 Years After Initial Diagnosis and a Matched General Population Cohort","authors":"John Acquavella, Dóra Körmendiné Farkas, Henrik Toft Sørensen","doi":"10.1002/cam4.70800","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>To determine whether mortality for patients with diffuse large B-cell lymphoma who survived 5 years (DLBCL5ys) returns thereafter to general population levels.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This population-based cohort study included Danish residents between January 1, 2000, and December 31, 2023. Information on diagnoses, comorbidities, and vital status came from Danish health and administrative registries. Analyses included 4164 DLBCL5yr patients—55% of incident patients—and 41,640 individuals from the general population matched 10:1 by exact birth year, sex, and the calendar year of achieving DLBCL5yr status. We used Cox proportional hazards models to compute matched mortality hazard ratios (HRs) and 95% confidence intervals (CIs) and controlled for comorbidities by adding Charlson comorbidity index scores to our models.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Mortality rates were elevated for DLBCL5yr patients soon after their 5-year survival date. The absolute difference in mortality was 20 deaths per 1000 person-years, and the HR adjusted for comorbidities was 1.5 (95% CI 1.4–1.6). Mortality was elevated similarly for men and women. The elevated mortality for DLBCL5yr patients varied in magnitude by age, calendar period, and comorbidity burden, and included excess mortality from DLBCL, cancers other than lymphoma, and respiratory diseases.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>We found that mortality for DLBCL5yr patients did not return to general population levels.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924275/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70800","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

To determine whether mortality for patients with diffuse large B-cell lymphoma who survived 5 years (DLBCL5ys) returns thereafter to general population levels.

Methods

This population-based cohort study included Danish residents between January 1, 2000, and December 31, 2023. Information on diagnoses, comorbidities, and vital status came from Danish health and administrative registries. Analyses included 4164 DLBCL5yr patients—55% of incident patients—and 41,640 individuals from the general population matched 10:1 by exact birth year, sex, and the calendar year of achieving DLBCL5yr status. We used Cox proportional hazards models to compute matched mortality hazard ratios (HRs) and 95% confidence intervals (CIs) and controlled for comorbidities by adding Charlson comorbidity index scores to our models.

Results

Mortality rates were elevated for DLBCL5yr patients soon after their 5-year survival date. The absolute difference in mortality was 20 deaths per 1000 person-years, and the HR adjusted for comorbidities was 1.5 (95% CI 1.4–1.6). Mortality was elevated similarly for men and women. The elevated mortality for DLBCL5yr patients varied in magnitude by age, calendar period, and comorbidity burden, and included excess mortality from DLBCL, cancers other than lymphoma, and respiratory diseases.

Conclusions

We found that mortality for DLBCL5yr patients did not return to general population levels.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.